FOI release

Disclosure log request: GLP1s

Case reference FOI2025/00447

Received 1 May 2025

Published 23 June 2025

Request

Please could you confirm: * How many UK spontaneous reports with GLP-1RAs, indicated for weight management, that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today)? * How many UK spontaneous reports with GLP-1RAs, linked to use for treating type 2 diabetes, that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today)? * How many UK spontaneous reports with GLP-1RAs, linked to with the treatment of weight management and diabetes in combination , that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today)? * How many UK spontaneous reports with GLP-1RAs, linked to with any treatment apart from type 2 diabetes or weight management, that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today)? And please could you : * Break down the total number of UK spontaneous reports with GLP-1RAs (linked to any treatment use) that report a fatal outcome the MHRA has received in total (ie: from the point of licensing until today) by the name of the GLP-1 agonist involved in the report.

Response

see attached

Documents

• FOI2025_00447 redacted for publication.pdf (111.6 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.